ライフサイエンスコーパス: ECT

1 ECT combines chemotherapy and electroporation to increas

2 ECT included three sessions per week for up to 6 weeks,

3 ECT induces functional neuroplasticity in the hippocampu

4 ECT is the most effective treatment for severe depressio

5 ECT occurs at a higher-than-expected rate in patients wi

6 ECT responders exhibited CBF increases in the dorsomedia

7 ECT uses HVEPs to transiently increase membrane permeabi

8 ECT was performed three times per week for the first 4 w

9 ECT-2, the exchange factor responsible for RhoA activati

10 ECT-2, the guanine nucleotide exchange factor (GEF) requ

11 ECT-induced neuroplasticity in the hippocampus and amygd

12 ntre, randomised, parallel-group study in 11 ECT suites serving inpatient and outpatient care setting

13 he kinesin MKLP1/ZEN-4, is known to activate ECT-2, but the underlying mechanism is not understood.

14 Whereas centralspindlin activates ECT-2 to promote cytokinetic contractile ring formation,

15 ated with right unilateral ultra-brief acute ECT.

16 ase, 70% responded and 47% remitted to acute ECT.

17 Additional ECT after remission (here operationalized as four contin

18 ECT treatments over 1 month, plus additional ECT as needed, using the Symptom-Titrated, Algorithm-Bas

19 d ECT to 6.6% among individuals administered ECT (risk ratio [RR], 0.54; 95% CI, 0.28-0.81).

20 ted 12.3% among individuals not administered ECT to 6.6% among individuals administered ECT (risk rat

21 l outcome, both after 2 treatments and after ECT index.

22 l connectivity in the brain before and after ECT treatment.

23 with depression (13F, 11M) before and after ECT, and 1 month after treatment.

24 set of brain connections whose changes after ECT can track patients' verbal memory impairments (r = 0

25 relationship, if any, with improvement after ECT.

26 ant increase in DG volume was observed after ECT (M = 75.44 mm(3), std error = 9.65, p < 0.001), whil

27 x and left postcentral gyrus/precuneus after ECT.

28 ant response differential was observed among ECT nonresponders (59.6% compared with 34.1%).

29 lafaxine plus lithium, over 24 weeks) and an ECT plus medication arm (four continuation ECT treatment

30 T, after two treatments, after completing an ECT treatment "index" (~4 weeks), and after long-term fo

31 er their second ECT, and after completing an ECT treatment index.

32 Two patients required the postponement of an ECT session because of mild confusion.

33 One group received an ECT series in addition to antidepressants (n = 24); a co

34 ge RP (CNTF3, and CNTF4) studies received an ECT-CNTF implant, designated as "NT-501," in one eye.

35 tivation, the catalytic domains of CYK-4 and ECT-2 directly interact.

36 Patients and assessment and ECT treatment teams were masked to treatment allocation,

37 IRE and ECT show immunogenic effects that could be augmented whe

38 enzodiazepines, antipsychotics, lithium, and ECT.

39 Future studies should compare MST and ECT under double-blind randomized condition.

40 The basis of the association between SJS and ECT is considered, as well as the role of plausible cont

41 tify patients with diagnoses of both SJS and ECT.

42 re identified with diagnoses of both SJS and ECT.

43 dividual components of chemoreceptor arrays, ECT has revealed the mesoscale information about how the

44 has been to bacterial chemoreceptor arrays, ECT's contributions to this field illustrate well its pa

45 tic insights into the actions of TurNP-based ECT treatment, we performed high-throughput, label-free

46 Patients were assessed before ECT, after their second ECT, and after completing an ECT

47 ponse in patients (n = 57, 30 female) before ECT, after two treatments, after completing an ECT treat

48 ic RhoGEF involves complex formation between ECT-2, centralspindlin and RhoA.

49 l (clozapine group) or a course of bilateral ECT plus clozapine (ECT plus clozapine group).

50 I scans: at baseline and after ten bilateral ECT sessions (corresponding to a 5-week interval).

51 instead proposed to activate Rho by binding ECT-2.

52 Bitemporal ECT was associated with a lower percent recall of autobi

53 ate-dose (1.5x seizure threshold) bitemporal ECT with high-dose unilateral ECT in real-world practice

54 ble patients, 69 were assigned to bitemporal ECT and 69 to unilateral ECT.

55 ight unilateral ECT is similar to bitemporal ECT but may have fewer cognitive side effects.

56 unilateral ECT is not inferior to bitemporal ECT for depression and may be preferable because of its

57 unilateral ECT was noninferior to bitemporal ECT regarding the 24-item HAM-D scores after the ECT cou

58 al network in prediction of response to both ECT and transcranial magnetic stimulation (TMS), offerin

59 thin different brain regions, are induced by ECT, the antidepressant-like effect of ECT in an animal

60 In human cells, ECT-2 activity requires its association with CYK-4, whic

61 or a course of bilateral ECT plus clozapine (ECT plus clozapine group).

62 tion of the safety and efficacy of combining ECT with pharmacological agents, including lithium, and

63 peated-measures modeling was used to compare ECT plus medication and medication alone for efficacy an

64 major depression in hospitals that conducted ECT fell from 70.5% to 44.7%, whereas receipt of ECT whe

65 ereas the percentage of hospitals conducting ECT decreased from 14.8% to 10.6%.

66 ly to receive care from hospitals conducting ECT.

67 bability that the treating hospital conducts ECT fell 34%, whereas probability of receiving ECT was u

68 the probability that their hospital conducts ECT.

69 46) were treated in a hospital that conducts ECT and, if so, received the procedure.

70 ma, logistics, and ethical factors constrain ECT administration in this condition and lead to its und

71 n (here operationalized as four continuation ECT treatments followed by further ECT only as needed) w

72 n ECT plus medication arm (four continuation ECT treatments over 1 month, plus additional ECT as need

73 he efficacy and tolerability of continuation ECT plus medication compared with medication alone in de

74 ithium) or pharmacotherapy plus continuation ECT.

75 assessed whether psychotherapy, continuation ECT, or antidepressant medication is the most efficaciou

76 was significantly less than for conventional ECT with high, fixed current (94-99%).

77 ss intense electric fields than conventional ECT that may be safer; efficacy and side effects should

78 The application of electron cryotomography (ECT) and new methods for fluorescent labelling of peptid

79 Electron cryotomography (ECT) can produce three-dimensional images of biological

80 Electron cryotomography (ECT) provides three-dimensional views of macromolecular

81 core, we have used electron cryotomography (ECT) to image infected cells and the viral particles cry

82 Using electron cryotomography (ECT), we find that CdvA polymerizes into helical filamen

83 Over the last two decades, ECT has revealed the ultrastructure of cells in unpreced

84 individuals with severe affective disorders, ECT's availability is limited and declining, suggesting

85 ase 1, depressed patients received high-dose ECT (at six times the seizure threshold) three times per

86 nts were randomly assigned to receive either ECT or algorithm-based pharmacological treatment.

87 ectroporation (IRE) and electrochemotherapy (ECT).

88 chemotherapy, known as electrochemotherapy (ECT) is gaining momentum as an attractive alternative.

89 urNP) therapy, known as Electrochemotherapy (ECT), to effectively target TNBC cells.

90 Standard electrochemotherapy (ECT) is effective in many tumour types but is confined t

91 ed by the guanine-nucleotide exchange factor ECT-2, is upstream of both myosin-II activation and diap

92 es model in all patients receiving the first ECT treatment.

93 on in the stimulation focality by 40-53% for ECT and 26% for MST, supporting amplitude individualizat

94 lization as a means of dosing especially for ECT.

95 onventional pulse amplitudes (112-174 mA for ECT and 37.4% of maximum device amplitude for MST).

96 ting the ECT treatment series), referred for ECT as part of their standard clinical care.

97 er alternative to empirical ST titration for ECT and MST.

98 Thus, large-format ECTs generated from hiPSC-derived cardiac cells may be f

99 delayed verbal recall (HVLT-R-DR) after four ECT treatments, using a Gaussian repeated measures model

100 ocality of stimulation in the brain for four ECT electrode configurations (bilateral, bifrontal, righ

101 tinuation ECT treatments followed by further ECT only as needed) was beneficial in sustaining mood im

102 Variable electrode-geometry ECT (VEG-ECT) may overcome these limitations by using lo

103 we show that the mammalian Rho GEF homolog, ECT-2, functions through the conserved RAS/ERK MAP kinas

104 However, ECT frequently results in episodic memory impairments, c

105 ions and/or circuits may be a way to improve ECT outcome.

106 ty can be rescued by activating mutations in ECT-2 or depletion of RGA-3/4, which functions as a conv

107 may contribute to antidepressant response in ECT, balanced plasticity in regions relevant to seizure

108 devices have focused attention on trends in ECT use, but current national data have been unavailable

109 ST was more variable in ECT than in MST.

110 our or more depression treatments (including ECT).

111 nt subgenual cingulate volume and individual ECT response (Montreal Neurological Institute [MNI] coor

112 Increased initial ECT cell number beyond 6 M per construct resulted in red

113 es derived from hiPSCs and incorporated into ECTs promotes functional maturation and demonstrates myo

114 tive study demonstrated that the intraocular ECT implant has a favorable pharmacokinetic profile for

115 tment gray matter volumes and to investigate ECT-related structural changes.

116 e annual number of inpatient stays involving ECT and proportion of general hospitals conducting the p

117 The annual number of stays involving ECT fell from 12.6 to 7.2/100,000 adult US residents, dr

118 s large-format engineered cardiac tissue (LF-ECT) composed of human induced pluripotent stem cells (h

119 mptom-Titrated, Algorithm-Based Longitudinal ECT [STABLE] algorithm, while continuing venlafaxine plu

120 ients typically require frequent maintenance ECT (mECT), as often as every 5 days, to sustain the imp

121 The CM+EC+MC ECTs implanted onto infarcted, immune tolerant rat heart

122 vitro force measurement showed that CM+EC+MC ECTs possessed preferential electromechanical properties

123 We generated a larger (30 x 30 mm) ME-ECT to confirm scalability.

124 ME-ECTs displayed the lowest dead cell ratio (p < 0.001) an

125 The 6M-ME-ECTs implanted onto 1 week post-infarct immune tolerant

126 We explored multiple 15 x 15 mm ECT geometries using molds with rectangular internal sta

127 among health care professionals about modern ECT technique.

128 ale; age=56.7 years [SD=14.8]) in a national ECT service with a 6-month follow-up.

129 contributes to the antidepressant action of ECT and implicate the ability of ECS to induce dendritic

130 The mode of action of ECT has even been ascribed to a "barbaric" form of place

131 Administration of ECT was associated with a reduced 30-day readmission ris

132 In the animal analog of ECT, neurogenesis in the dentate gyrus (DG) of the hippo

133 we determine the effects of diagnosis and of ECT on global and local variations of hippocampal and am

134 ld exposure in the brain, but this aspect of ECT dosing is largely unexplored.

135 Ketamine augmentation of ECT (five trials encompassing 89 ketamine-treated partic

136 ecision making regarding the availability of ECT.

137 t but functionally related in the context of ECT response.

138 obit model of the association correlation of ECT administration with patient risk of 30-day readmissi

139 iatric patients after a successful course of ECT (phase 1).

140 issues in the administration of a course of ECT, including the consent process.

141 potential role of these models in dosing of ECT and MST.

142 ed by ECT, the antidepressant-like effect of ECT in an animal model depends on reduction of VTA BDNF

143 on blocked the antidepressant-like effect of ECT.

144 the individual therapeutic effectiveness of ECT.

145 l role in the antidepressant-like effects of ECT and performed a direct comparison between BDNF manip

146 cts of diagnosis and longitudinal effects of ECT for volume and surface-based shape metrics of the ca

147 mation about the population-level effects of ECT is needed.

148 y specific, spatially distributed effects of ECT on regional brain structure in two populations: pati

149 the evidence base supporting the efficacy of ECT to treat severe depression in elderly patients.

150 We also discuss the integration of ECT with other techniques, including lower-resolution fl

151 subgroups, analyses included interactions of ECT with age group, sex, race/ethnicity, and diagnosis g

152 um, our results suggest that the location of ECT-related plasticity within the hippocampus may differ

153 They compared efficacy measures of ECT and algorithm-based pharmacological treatment in tre

154 in insight into the anticancer mechanisms of ECT using electrical pulses (EP) and Cisplatin (CsP) on

155 The mean number of ECT treatments to remission was 7.3 (SD=3.1).

156 manipulations on antidepressant outcomes of ECT were evaluated by the forced swim test and by sucros

157 ich could represent functional precursors of ECT-induced increases in hippocampal volume reported pre

158 ification yielded a successful prediction of ECT response, with accuracy rates of 78.3% (18 of 23 pat

159 ral plasticity relating to and predictive of ECT response may point to the mechanisms underlying rapi

160 ngual gyrus were identified as predictors of ECT response, achieving accuracy of 89, 90 and 86% for r

161 ctures in major depression and predictors of ECT-related clinical response.

162 The prevalence of ECT in this population exceeded that in the general popu

163 related to the antidepressant properties of ECT, and may reflect neurogenesis.

164 fell from 70.5% to 44.7%, whereas receipt of ECT where conducted declined from 12.9% to 10.5%.

165 vidence regarding the efficacy and safety of ECT in mania, including related syndromes, such as delir

166 In all cases, the m(6)A-binding site of ECT proteins is required for in vivo function.

167 ealed that diagnosis of SJS preceded that of ECT.

168 apine group received an 8-week open trial of ECT (crossover phase).

169 the functional connectivity underpinnings of ECT-induced episodic memory impairments.

170 ed, suggesting that CYK-4 is not upstream of ECT-2/Rho activation.

171 ogical agents, including lithium, and use of ECT as a maintenance strategy have enhanced our understa

172 The authors examined the use of ECT as an augmentation to clozapine for treatment-refrac

173 uced promising research regarding the use of ECT in mania.

174 determined the impact of cell composition on ECT structural and functional properties.

175 inesis failure due to disruption of CYK-4 or ECT-2 but does not rescue cytokinesis failure due to dis

176 nt-to-treat sample included 39 participants (ECT plus clozapine group, N=20; clozapine group, N=19).

177 e either baseline memory performance or post-ECT verbal memory impairments.

178 Here we aim to predict post-ECT depressive rating changes and remission status using

179 Secondary outcome measures were post-ECT reorientation and safety.

180 ating changes and remission status using pre-ECT gray matter (GM) in 38 MDD patients and validate in

181 y pattern classification was used to predict ECT response by structural MRI that was performed before

182 morphometric measures at baseline predicted ECT-related clinical response.

183 al CBF associated with clinically prescribed ECT and therapeutic response in patients (n = 57, 30 fem

184 l alignment and higher active stress than PS-ECTs.

185 These results suggest that ultra-brief pulse ECT as a continuation treatment correlates with low sust

186 acy studies, using thrice-weekly brief-pulse ECT, reported that high-dose (6x seizure threshold) righ

187 course of right unilateral ultrabrief pulse ECT, augmented with venlafaxine.

188 course of right unilateral ultrabrief pulse ECT, combined with open-label venlafaxine at seven acade

189 Right unilateral ultrabrief pulse ECT, combined with venlafaxine, is a rapidly acting and

190 9 patients from the clozapine group received ECT in the crossover phase.

191 T fell 34%, whereas probability of receiving ECT was unchanged for patients treated in facilities tha

192 None of the patients required ECT.

193 f a contractile ring and requires the RhoGEF ECT-2, a RhoA activator also essential for cytokinesis.

194 e of adjunctive low-dose ketamine in routine ECT treatment.

195 three times: prior to ECT, after the second ECT session, and within 1 week of completing the ECT tre

196 were assessed before ECT, after their second ECT, and after completing an ECT treatment index.

197 eatment to sustain response after successful ECT in MDD patients.

198 Another report (N=34) described successful ECT treatment.

199 a weaker and more focal electric field than ECT; however, the pulse amplitude is not individualized

200 le to cap coil MST (23%), demonstrating that ECT with a low current amplitude and focal electrode pla

201 Importantly, we found that ECT caused a robust reduction in VTA BDNF levels.

202 We report that ECT-2-mediated RhoA activation depends on the ability of

203 ixed-effects modeling analysis revealed that ECT was significantly more effective than algorithm-base

204 e, and hippocampal networks, suggesting that ECT affects broad functional networks that are involved

205 Results support that ECT elicits structural plasticity in the dorsal and vent

206 regarding the 24-item HAM-D scores after the ECT course (mean difference=1.08 points in favor of unil

207 ression Rating Scale (HAM-D) score after the ECT course; the prespecified noninferiority margin was 4

208 session, and within 1 week of completing the ECT treatment series), referred for ECT as part of their

209 monstrate that this mutation facilitates the ECT in Escherichia coli SecA and triggers it completely

210 e 6-week treatment period were lower for the ECT group than for the pharmacological treatment group:

211 esponse rate was significantly higher in the ECT group than in the group that received algorithm-base

212 Significantly more patients in the ECT plus medication group were rated "not ill at all" on

213 aled a increase in hippocampal volume in the ECT sample (MNI coordinates x = -28, y = -9, z = -18; Z

214 One participant in the ECT sample was excluded from the analysis, leaving 67 pa

215 acy rates of 78.3% (18 of 23 patients in the ECT sample) and sensitivity rates of 100% (13 of 13 who

216 onse rates of 65% in the CBT-arm, 28% in the ECT-arm, and 33% in the MED-arm.

217 onse rates of 77% in the CBT-arm, 40% in the ECT-arm, and 44% in the MED-arm.

218 s' g=0.933) but not at the conclusion of the ECT course.

219 Fifty percent of the ECT plus clozapine patients met the response criterion.

220 ase in entropy observed in the course of the ECT, hydrogen-deuterium exchange mass spectrometry demon

221 contractile ring formation, we show that the ECT-2 regulator NOP-1, but not centralspindlin, is essen

222 T) using single pulses delivered through the ECT electrodes or MST coil.

223 to quantitatively identify and validate the ECT treatment biomarkers using multi-site GM data.

224 At 24 weeks, the ECT plus medication group had statistically significantl

225 to the anaesthetic for the duration of their ECT course.

226 Electroconvulsive therapy (ECT) at conventional current amplitudes (800-900 mA) is

227 We have found electroconvulsive therapy (ECT) can produce life-changing results, with more than 9

228 ultrabrief pulse electroconvulsive therapy (ECT) combined with venlafaxine for the treatment of geri

229 ral regulation of electroconvulsive therapy (ECT) devices have focused attention on trends in ECT use

230 Electroconvulsive therapy (ECT) elicits a rapid and robust clinical response in pat

231 erning the use of electroconvulsive therapy (ECT) for psychiatric disorders stemming from a lack of i

232 rent amplitude in electroconvulsive therapy (ECT) has been proposed as a means to produce stimulation

233 Electroconvulsive therapy (ECT) has been repeatedly linked to hippocampal plasticit

234 nce suggests that electroconvulsive therapy (ECT) induces neuroplasticity in patients with severe dep

235 Electroconvulsive therapy (ECT) is a robust and rapidly acting treatment for severe

236 Electroconvulsive therapy (ECT) is an effective treatment for severe medication-res

237 Although electroconvulsive therapy (ECT) is considered the most efficacious treatment availa

238 Electroconvulsive therapy (ECT) is effective for major depressive disorder (MDD) bu

239 The use of electroconvulsive therapy (ECT) is limited by concerns about its cognitive adverse

240 Electroconvulsive therapy (ECT) is one of the most effective treatments for severe

241 Electroconvulsive therapy (ECT) is regarded by many clinicians as the most effectiv

242 Although electroconvulsive therapy (ECT) is the most effective acute antidepressant interven

243 Electroconvulsive therapy (ECT) is the most effective treatment for depression, yet

244 with response to electroconvulsive therapy (ECT) remain limited, and focused on interactions between

245 clinical effects, electroconvulsive therapy (ECT) represents an optimal model to develop and test tre

246 s associated with electroconvulsive therapy (ECT), a highly effective and commonly used antidepressan

247 n, in the form of electroconvulsive therapy (ECT), has long been a gold standard treatment for depres

248 ctice guidelines, electroconvulsive therapy (ECT), once a widely used standalone intervention for man

249 Electroconvulsive therapy (ECT), which has been in use for 75 years, is an importan

250 atments including electroconvulsive therapy (ECT).

251 ulse continuation electroconvulsive therapy (ECT-arm), or no add-on therapy (MED-arm).

252 d thrombin time (dTT), ecarin clotting time (ECT), activated partial thromboplastin time (aPTT), and

253 We generated engineered cardiac tissues (ECTs) from three cellular compositions of cardiomyocytes

254 therapy (MST) is a potential alternative to ECT that may not adversely affect memory.

255 bipolar disorders respond differentially to ECT and the associated local brain-volume changes, which

256 c seizure therapy (MST), or modifications to ECT.

257 parately for responders and nonresponders to ECT.

258 ssion (N = 43, scanned three times: prior to ECT, after the second ECT session, and within 1 week of

259 ew the basic and clinical science related to ECT's mechanism of action and discuss clinical issues in

260 ne global CBF were more likely to respond to ECT.

261 ity rates of 100% (13 of 13 who responded to ECT).

262 relate to or predict therapeutic response to ECT is unknown.

263 arkers that accurately predict a response to ECT remain unidentified.

264 shape metrics predicted overall response to ECT with up to 89% accuracy.

265 among patients with a history of response to ECT, those in the adjunctive VNS group had a significant

266 city plays in the antidepressant response to ECT.

267 lated endothermic conformational transition (ECT) believed to involve similar structural mechanics to

268 limited numbers, the adoption of ultrabrief ECT, examination of the safety and efficacy of combining

269 86 of the 162691 inpatients (1.5%) underwent ECT during their index admission.

270 Twenty-five patients underwent ECT for the treatment of non-melanoma head and neck canc

271 ld) bitemporal ECT with high-dose unilateral ECT in real-world practice.

272 Twice-weekly high-dose unilateral ECT is not inferior to bitemporal ECT for depression and

273 High-dose unilateral ECT was noninferior to bitemporal ECT regarding the 24-i

274 signed to bitemporal or high-dose unilateral ECT.

275 orientation was quicker following unilateral ECT (median=19.1 minutes versus 26.4 minutes).

276 ifference=1.08 points in favor of unilateral ECT [95% CI=-1.67 to 3.84]).

277 dose (6x seizure threshold) right unilateral ECT is similar to bitemporal ECT but may have fewer cogn

278 ality of amplitude-titrated right-unilateral ECT (25%) was comparable to cap coil MST (23%), demonstr

279 igned to bitemporal ECT and 69 to unilateral ECT.

280 complex in a physiological context, we used ECT to image the archaeon Sulfolobus acidocaldarius and

281 heva et al. examined sporulating cells using ECT and fluorescence microscopy to demonstrate the conti

282 ombined visualization of peptidoglycan using ECT with molecular modelling of three proposed arrangeme

283 VEG-ECT demonstrated encouraging antitumour activity in soft

284 Variable electrode-geometry ECT (VEG-ECT) may overcome these limitations by using long freely

285 1667954) and received a single course of VEG-ECT with intravenous bleomycin (15,000 IU/m(2)) and conc

286 erential electromechanical properties versus ECTs without vascular cells indicating that incorporatio

287 al thalamus and motor cortex near the vertex ECT electrode, as well as decreased CBF within lateral f

288 strumental variable used in the analysis was ECT prevalence in the prior calendar year at the treatin

289 Here, we show that whereas ECT increased hippocampal BDNF expression, induction of

290 To examine whether ECT's association with readmissions was heterogeneous ac

291 gs shed light on the mechanism through which ECT impairs episodic memory, and additionally underline

292 t an illustrative case of a patient for whom ECT is indicated.

293 Significantly larger associations with ECT on readmission risk were found for men compared with

294 The augmentation of clozapine with ECT is a safe and effective treatment option.

295 mpal and the amygdala volumes increased with ECT (p < .001) and in relation to symptom improvement (p

296 ering the glutamate antagonist ketamine with ECT might alleviate cognitive adverse effects and accele

297 n left putamen volume (P<0.03) occurred with ECT.

298 amplitude required to induce a seizure with ECT (bilateral, right unilateral, bifrontal, and frontom

299 To examine whether inpatient treatment with ECT is associated with a reduction in 30-day psychiatric

300 be associated with successful treatment with ECT.